Search Within

Martin Henner Voss

Formats
  1. Meeting Abstract (150)
  2. Journal Article (122)
  3. Review (6)
  4. Editorial (5)
  5. Guidelines (2)
  6. Research Letter (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (288)
  2. Genitourinary Oncology Service (288)
  3. Solid Tumor Oncology Division (288)
  4. Human Oncology and Pathogenesis Program (104)
  5. Weinberg Fellows (104)
  6. Surgery (103)

More Groups

People
  1. Robert Motzer (176)
  2. Abraham Hakimi (95)
  3. Darren Feldman (80)
  4. Chung-Han Lee (75)
  5. Maria Carlo (65)
  6. Ritesh Kotecha (63)

More People

Years
  1. 2025 (6)
  2. 2024 (15)
  3. 2023 (21)
  4. 2022 (24)
  5. 2021 (30)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (116)
  2. Clinical Cancer Research (18)
  3. BJU International (15)
  4. Annals of Oncology (13)
  5. Journal for ImmunoTherapy of Cancer (12)
  6. Clinical Genitourinary Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (120)
  2. American Association for Cancer Research (26)
  3. Wiley Blackwell (22)
  4. Elsevier Inc. (21)
  5. Oxford University Press (18)
  6. Biomed Central Ltd (15)

More Publishers

Results (288)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical and immunogenomic outcomes of consolidative cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint blockade
    Meeting Abstract

    Reese, S. W.; Jiang, H.; Kuo, F.; Wu, C. Y.; Vuong, L.; Mascareno, E.; Oparanozie, A.; Motzer, R. J.; Voss, M. H.; Reznik, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Correlating HLA variants and the emergence of immune-related adverse events (irAEs) from ipilimumab/nivolumab (I/N) in patients (pts) treated on CheckMate 214
    Meeting Abstract

    Voss, M. H.; Shah, N. J.; Kalvin, H. L.; Lihm, J.; Li, H.; Kotecha, R. R.; Jarchum, I.; Vemula, S. V.; Gupta, S.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Matched molecular profiling of cell-free DNA and tumor tissue in patients with advanced clear cell renal cell carcinoma
    Journal Article

    Kotecha, R. R.; Gedvilaite, E.; Ptashkin, R.; Knezevic, A.; Murray, S.; Johnson, I.; Shapnik, N.; Feldman, D. R.; Carlo, M. I.; Shah, N. J.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape
    Journal Article

    Golkaram, M.; Kuo, F.; Gupta, S.; Carlo, M. I.; Salmans, M. L.; Vijayaraghavan, R.; Tang, C.; Makarov, V.; Rappold, P.; Blum, K. A.; more...
    Genome Medicine (2022)

    Fulltext@MSK | Save
  • Associations between pretreatment body composition features and clinical outcomes among patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint blockade
    Journal Article

    Ged, Y.; Sanchez, A.; Patil, S.; Knezevic, A.; Stein, E.; Petruzella, S.; Weiss, K.; Duzgol, C.; Chaim, J.; Akin, O.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study
    Meeting Abstract

    Voss, M. H.; Powles, T.; McGregor, B. A.; Porta, C.; Grünwald, V.; Merchan, J. R.; Rolland, F.; Maroto-Rey, P.; Goh, J. C.; Xing, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Long-term outcomes of adrenal insufficiency (AI) due to anti-PD(L)-1 immune checkpoint inhibitors (ICI) among patients with cancer
    Meeting Abstract

    Nguyen, B.; Shah, N. J.; Knezevic, A.; Newman, S.; Fitzgerald, K. N.; Kotecha, R.; Lee, C. H.; Carlo, M. I.; Aggen, D. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Molecular profile and clinical outcomes of renal cell carcinoma brain metastases treated with stereotactic radiosurgery
    Meeting Abstract

    Ma, J.; del Balzo, L.; Khaleel, S. S.; Flynn, J.; Zhang, Z.; Voss, M. H.; Freeman, B.; Hakimi, A. A.; Lee, C. H.; Eichholz, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A robust, trial-agnostic gene signature for response to tyrosine kinase inhibition in ccRRCC
    Meeting Abstract

    Khaleel, S. S.; Liu, M.; Kuo, F.; Kotecha, R.; Lee, C. H.; Voss, M. H.; Motzer, R. J.; Hakimi, A. A.; Reznik, E.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save